Windtree Therapeutics acquires Varian Biopharmaceuticals’ assets
Windtree Therapeutics, Inc. (NasdaqCM: WINT) has announced the acquisition of a novel oncology asset platform from Varian Biopharmaceuticals, Inc., including an atypical protein kinase C iota inhibitor (aPKCi), and the completion of a $1.5 million convertible note bridge financing. The…